Clinical failure · acute rhinosinusitis in adults, whether clinically diagnosed or confirmed by imaging
Antibiotics leads to lower clinical failure compared with placebo (high certainty).
1 finding from 1 review
Visual improvement at end of treatment, as defined by two or more Snellen lines · people with diabetic retinopathy
Single herb plus conventional intervention may leads to higher visual acuity (gain of ≥ 2 lines) (end of treatment) compared with conventional intervention (low certainty).
1 finding from 1 review
Reduction in microaneurysms · people with diabetic retinopathy
It is very uncertain whether single herb plus conventional intervention changes reduction in microaneurysms compared with conventional intervention (very low certainty).
1 finding from 1 review
Observations in retina: reduction in haemorrhages · people with diabetic retinopathy
It is very uncertain whether single herb plus conventional intervention changes observations in retina: reduction in haemorrhages compared with conventional intervention (very low certainty).
1 finding from 1 review
HbA1c (%) · people with diabetic retinopathy
1 finding from 1 review
Adverse outcomes · people with diabetic retinopathy
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine changes overall response rate compared with vandetanib (very low certainty).
1 finding from 1 review
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine changes grade 1 ‐ 4 anaemia compared with vandetanib (very low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus cisplatin changes all‐cause mortality at 1 year compared with S‐1 plus cisplatin (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus cisplatin changes overall response rate compared with S‐1 plus cisplatin (very low certainty).
1 finding from 1 review
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus cisplatin changes grade 1 ‐ 4 anaemia compared with S‐1 plus cisplatin (very low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes all‐cause mortality at 1 year compared with S‐1 (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus vandetanib changes serious adverse events compared with vandetanib (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes serious adverse events compared with S‐1 (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found